Moderna shares fall after FDA refuses to review new flu vaccine

Core Viewpoint - Moderna shares experienced a 14% decline in Frankfurt following the U.S. FDA's refusal to review the company's influenza vaccine approval application [1] Company Summary - Moderna's stock opened 14% lower in Frankfurt, indicating a significant market reaction to the FDA's decision [1] - The trading volume was low, suggesting limited investor activity during this period [1] Industry Summary - The refusal by the U.S. FDA to review the influenza vaccine application may impact the broader vaccine market and investor sentiment towards vaccine developers [1]